Merck Highlights 10 Years Data from the P-III (KEYNOTE-006) Study of Keytruda in Advanced Melanoma Patients at ESMO 2024
Shots:
- The P-III (KEYNOTE-006) trial assessed Keytruda vs ipilimumab to treat advanced melanoma; participants could transition to the KEYNOTE-587 extension study for long-term follow-up. Results include 10yrs. follow-up data for 211 patients
- Results at a median follow-up of 123.7mos. (time of study entry in KEYNOTE-006 to data cut-off for KEYNOTE-587) showed improved OS & PFS, with an mOS of 32.7mos. vs 15.9mos. and a 10yr. OS rate of 34% vs 23.6%, modified mPFS was 9.4mos. vs 3.8mos. Keytruda reduced death risk by 29%
- The final analysis of KEYNOTE-006 at a median follow-up of 32mos. showed 55.1% (Q2W) & 55.3% (Q3W) vs 43.0% of patients were alive at 2yrs. Data was published in the Annals of Oncology
Ref: Merck | Image: Merck
Related News:- GI Innovation Join Forces with Merck to Evaluate GI-102 Plus Keytruda for Treating Various Cancers
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
